Predictive Value of Excision Repair Cross Complementation Group 1 (ERCC1) by Immunohistochemistry for Determining Neoadjuvant Chemotherapy Response in Triple-Negative Breast Cancers

Conclusion: In this study, we established the role of negative ERCC1 expression in predicting the response to chemotherapy in neoadjuvant TNBC. Therefore, ERCC1 can be used as a predictive marker to stratify patients who will benefit from neoadjuvant therapy. Moreover, we also noted an association b...

Full description

Saved in:
Bibliographic Details
Main Authors: Atif Ali Hashmi, Yumna Ajaz, Muhsana Sajjad, Fazail Zia, Muhammad Irfan, Syed Muhammad Abu Bakar, Erum Yousuf Khan, Naveen Faridi
Format: Article
Language:English
Published: Wiley 2025-01-01
Series:The Breast Journal
Online Access:http://dx.doi.org/10.1155/tbj/8410670
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850231664362389504
author Atif Ali Hashmi
Yumna Ajaz
Muhsana Sajjad
Fazail Zia
Muhammad Irfan
Syed Muhammad Abu Bakar
Erum Yousuf Khan
Naveen Faridi
author_facet Atif Ali Hashmi
Yumna Ajaz
Muhsana Sajjad
Fazail Zia
Muhammad Irfan
Syed Muhammad Abu Bakar
Erum Yousuf Khan
Naveen Faridi
author_sort Atif Ali Hashmi
collection DOAJ
description Conclusion: In this study, we established the role of negative ERCC1 expression in predicting the response to chemotherapy in neoadjuvant TNBC. Therefore, ERCC1 can be used as a predictive marker to stratify patients who will benefit from neoadjuvant therapy. Moreover, we also noted an association between ERCC1 expression and nodal metastasis; however, more large-scale studies are needed to establish its role as a prognostic biomarker in TNBC.
format Article
id doaj-art-81aa624dd8ff413f8f3f86221cea9b68
institution OA Journals
issn 1524-4741
language English
publishDate 2025-01-01
publisher Wiley
record_format Article
series The Breast Journal
spelling doaj-art-81aa624dd8ff413f8f3f86221cea9b682025-08-20T02:03:27ZengWileyThe Breast Journal1524-47412025-01-01202510.1155/tbj/8410670Predictive Value of Excision Repair Cross Complementation Group 1 (ERCC1) by Immunohistochemistry for Determining Neoadjuvant Chemotherapy Response in Triple-Negative Breast CancersAtif Ali Hashmi0Yumna Ajaz1Muhsana Sajjad2Fazail Zia3Muhammad Irfan4Syed Muhammad Abu Bakar5Erum Yousuf Khan6Naveen Faridi7Department of HistopathologyDepartment of HistopathologyDepartment of PathologyDepartment of PathologyDepartment of StatisticsDepartment of HistopathologyDepartment of HistopathologyDepartment of HistopathologyConclusion: In this study, we established the role of negative ERCC1 expression in predicting the response to chemotherapy in neoadjuvant TNBC. Therefore, ERCC1 can be used as a predictive marker to stratify patients who will benefit from neoadjuvant therapy. Moreover, we also noted an association between ERCC1 expression and nodal metastasis; however, more large-scale studies are needed to establish its role as a prognostic biomarker in TNBC.http://dx.doi.org/10.1155/tbj/8410670
spellingShingle Atif Ali Hashmi
Yumna Ajaz
Muhsana Sajjad
Fazail Zia
Muhammad Irfan
Syed Muhammad Abu Bakar
Erum Yousuf Khan
Naveen Faridi
Predictive Value of Excision Repair Cross Complementation Group 1 (ERCC1) by Immunohistochemistry for Determining Neoadjuvant Chemotherapy Response in Triple-Negative Breast Cancers
The Breast Journal
title Predictive Value of Excision Repair Cross Complementation Group 1 (ERCC1) by Immunohistochemistry for Determining Neoadjuvant Chemotherapy Response in Triple-Negative Breast Cancers
title_full Predictive Value of Excision Repair Cross Complementation Group 1 (ERCC1) by Immunohistochemistry for Determining Neoadjuvant Chemotherapy Response in Triple-Negative Breast Cancers
title_fullStr Predictive Value of Excision Repair Cross Complementation Group 1 (ERCC1) by Immunohistochemistry for Determining Neoadjuvant Chemotherapy Response in Triple-Negative Breast Cancers
title_full_unstemmed Predictive Value of Excision Repair Cross Complementation Group 1 (ERCC1) by Immunohistochemistry for Determining Neoadjuvant Chemotherapy Response in Triple-Negative Breast Cancers
title_short Predictive Value of Excision Repair Cross Complementation Group 1 (ERCC1) by Immunohistochemistry for Determining Neoadjuvant Chemotherapy Response in Triple-Negative Breast Cancers
title_sort predictive value of excision repair cross complementation group 1 ercc1 by immunohistochemistry for determining neoadjuvant chemotherapy response in triple negative breast cancers
url http://dx.doi.org/10.1155/tbj/8410670
work_keys_str_mv AT atifalihashmi predictivevalueofexcisionrepaircrosscomplementationgroup1ercc1byimmunohistochemistryfordeterminingneoadjuvantchemotherapyresponseintriplenegativebreastcancers
AT yumnaajaz predictivevalueofexcisionrepaircrosscomplementationgroup1ercc1byimmunohistochemistryfordeterminingneoadjuvantchemotherapyresponseintriplenegativebreastcancers
AT muhsanasajjad predictivevalueofexcisionrepaircrosscomplementationgroup1ercc1byimmunohistochemistryfordeterminingneoadjuvantchemotherapyresponseintriplenegativebreastcancers
AT fazailzia predictivevalueofexcisionrepaircrosscomplementationgroup1ercc1byimmunohistochemistryfordeterminingneoadjuvantchemotherapyresponseintriplenegativebreastcancers
AT muhammadirfan predictivevalueofexcisionrepaircrosscomplementationgroup1ercc1byimmunohistochemistryfordeterminingneoadjuvantchemotherapyresponseintriplenegativebreastcancers
AT syedmuhammadabubakar predictivevalueofexcisionrepaircrosscomplementationgroup1ercc1byimmunohistochemistryfordeterminingneoadjuvantchemotherapyresponseintriplenegativebreastcancers
AT erumyousufkhan predictivevalueofexcisionrepaircrosscomplementationgroup1ercc1byimmunohistochemistryfordeterminingneoadjuvantchemotherapyresponseintriplenegativebreastcancers
AT naveenfaridi predictivevalueofexcisionrepaircrosscomplementationgroup1ercc1byimmunohistochemistryfordeterminingneoadjuvantchemotherapyresponseintriplenegativebreastcancers